By Matthew Pillar, Editor, Bioprocess Online
How does a biopharma business that’s potentially years away from its first shot at therapeutic sales revenue thrive in a high-inflation, high-interest, supply-constrained business environment?
It might do well to study the playbook of a more innovative peer. Episode 103 of the “Business of Biotech” podcast offers a case in point. Our conversation with Philogen CEO, CSO, and cofounder Prof. Dario Neri, Ph.D. reveals his company’s metered emergence from academia, its avoidance of venture capital, and its rapid realization of revenue through pre-pipeline collaboration.